Literature DB >> 21845496

Comparison of clinicopathologic factors in 122 patients with resected pancreatic and ileal neuroendocrine tumors from a single institution.

Fadi S Dahdaleh1, Daniel Calva-Cerqueira, Jennifer C Carr, Junlin Liao, James J Mezhir, Thomas M O'Dorisio, James R Howe.   

Abstract

BACKGROUND: Recent population-based studies have demonstrated significant differences in outcome between patients with pancreatic and ileal neuroendocrine tumors. The objective of this study was to examine the clinicopathologic differences between ileal and pancreatic neuroendocrine tumors following resection.
METHODS: A retrospective chart review was performed and data on clinicopathologic variables, biochemical markers, and follow-up of patients with resected ileal (INETs) and pancreatic (PNETs) neuroendocrine tumors were collected. The t test or analysis of variance (ANOVA) was used to compare means. Survival analysis was performed using the Kaplan-Meier method.
RESULTS: Between 1998 and 2010, 122 patients with PNETs and INETs were explored (70 PNETs and 52 INETs). Several variables were found to be significantly different between patients in both groups. INETs were more often associated with flushing (44 vs. 14%; P < 0.001) and diarrhea (63 vs. 16%; P < 0.001) and were more often associated with elevation in preoperative serum levels of pancreastatin (88 vs. 42%; P < 0.001), chromogranin A (78 vs. 54%; P = 0.036), and serotonin (90 vs. 43%; P < 0.001). INETs more frequently had vascular invasion on pathology (96 vs. 60%; P < 0.001), and presented more often with nodal and/or distant metastases (77 vs. 37%; P < 0.001). There was no significant difference in overall survival between patients in both groups.
CONCLUSION: In this series, patients with INETs presented with a more advanced stage of disease compared with PNETs, had higher preoperative levels of 3 markers, and were more often symptomatic. Despite these factors, there was no significant difference in overall survival between patients with these 2 tumor types.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21845496     DOI: 10.1245/s10434-011-1997-4

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  14 in total

1.  Pancreastatin predicts survival in neuroendocrine tumors.

Authors:  Scott K Sherman; Jessica E Maxwell; M Sue O'Dorisio; Thomas M O'Dorisio; James R Howe
Journal:  Ann Surg Oncol       Date:  2014-04-22       Impact factor: 5.344

2.  GIPR expression in gastric and duodenal neuroendocrine tumors.

Authors:  Scott K Sherman; Jessica E Maxwell; Jennifer C Carr; Donghong Wang; M Sue O'Dorisio; Thomas M O'Dorisio; James R Howe
Journal:  J Surg Res       Date:  2014-01-29       Impact factor: 2.192

3.  RABL6A promotes G1-S phase progression and pancreatic neuroendocrine tumor cell proliferation in an Rb1-dependent manner.

Authors:  Jussara Hagen; Viviane P Muniz; Kelly C Falls; Sara M Reed; Agshin F Taghiyev; Frederick W Quelle; Francoise A Gourronc; Aloysius J Klingelhutz; Heather J Major; Ryan W Askeland; Scott K Sherman; Thomas M O'Dorisio; Andrew M Bellizzi; James R Howe; Benjamin W Darbro; Dawn E Quelle
Journal:  Cancer Res       Date:  2014-10-01       Impact factor: 12.701

4.  Small Bowel Neuroendocrine Tumors.

Authors:  Catherine G Tran; Scott K Sherman; James R Howe
Journal:  Curr Probl Surg       Date:  2020-05-15       Impact factor: 1.909

Review 5.  The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society.

Authors:  James R Howe; Kenneth Cardona; Douglas L Fraker; Electron Kebebew; Brian R Untch; Yi-Zarn Wang; Calvin H Law; Eric H Liu; Michelle K Kim; Yusuf Menda; Brian G Morse; Emily K Bergsland; Jonathan R Strosberg; Eric K Nakakura; Rodney F Pommier
Journal:  Pancreas       Date:  2017-07       Impact factor: 3.327

6.  Differentiation of small bowel and pancreatic neuroendocrine tumors by gene-expression profiling.

Authors:  Jennifer C Carr; Erin A Boese; Philip M Spanheimer; Fadi S Dahdaleh; Molly Martin; Daniel Calva; Blanca Schafer; David M Thole; Terry Braun; Thomas M O'Dorisio; M Sue O'Dorisio; James R Howe
Journal:  Surgery       Date:  2012-12       Impact factor: 3.982

7.  Gastric inhibitory polypeptide receptor (GIPR) is a promising target for imaging and therapy in neuroendocrine tumors.

Authors:  Scott K Sherman; Jennifer C Carr; Donghong Wang; M Sue O'Dorisio; Thomas M O'Dorisio; James R Howe
Journal:  Surgery       Date:  2013-12       Impact factor: 3.982

Review 8.  Workup of Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Joseph S Dillon
Journal:  Surg Oncol Clin N Am       Date:  2020-04       Impact factor: 3.495

9.  Neuroendocrine tumors arising in Meckel's diverticula: frequency of advanced disease warrants aggressive management.

Authors:  Allison W Lorenzen; Thomas M O'Dorisio; James R Howe
Journal:  J Gastrointest Surg       Date:  2013-04-05       Impact factor: 3.452

10.  Gene expression accurately distinguishes liver metastases of small bowel and pancreas neuroendocrine tumors.

Authors:  Scott K Sherman; Jessica E Maxwell; Jennifer C Carr; Donghong Wang; Andrew M Bellizzi; M Sue O'Dorisio; Thomas M O'Dorisio; James R Howe
Journal:  Clin Exp Metastasis       Date:  2014-09-21       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.